Related Experiment Videos
Considerations in the use of biochemical markers of ischemic injury
Insights
Estimating infarct size using creatine phosphokinase (CPK) helps predict patient prognosis and treatment effectiveness. Refined models, considering noncardiac CPK sources and physiological factors, improve accuracy for assessing myocardial infarction severity.
Area of Science:
- Biochemistry
- Cardiology
- Medical Diagnostics
Background:
- Creatine phosphokinase (CPK) levels in blood are used to estimate infarct size.
- Infarct size impacts prognosis, ventricular function, and clinical manifestation severity.
- Accurate estimation requires accounting for noncardiac CPK sources and physiological influences.
Purpose of the Study:
- To refine infarct size estimation using biochemical markers.
- To improve the accuracy of mathematical models for assessing myocardial infarction.
Main Methods:
- Utilizing MB CPK instead of total CPK to exclude noncardiac sources.
- Developing and applying physiologically based mathematical models for CPK release and disappearance.
- Investigating CPK inactivation in lymph.
Main Results:
- Using MB CPK improves enzymatic estimates of infarct size.
- CPK release from infarcts may be diffusion-limited.
- CPK disappearance rate is minimally affected by hemodynamic derangements or myocardial infarction.
Conclusions:
- Accurate infarct size estimation is crucial for prognosis and therapeutic evaluation.
- Mathematical models need to incorporate factors influencing marker levels in circulation.
- Understanding CPK kinetics and inactivation is key to quantifying ischemic injury.
Abstract:
Results of estimation of infarct size with a selected biochemical marker in blood, creatine phosphokinase (CPK), have suggested that infarct size is an important determinant of prognosis, impaired ventricular function, early ventricular dysrhythmia, and the severity of clinical manifestations. Estimates based on serial changes in serum CPK activity have correlated with morphological estimates and have been employed to evaluate therapeutic interventions. Improved estimates with any biochemical marker require exclusion of noncardiac sources of the marker and characterization of the influence of physiological alterations on parameters in empirical or physiologically based mathematical models utilized. Use of MB CPK instead of total CPK therefore improves enzymatic estimates when infarction is accompanied by release of noncardiac CPK into the circulation. Preliminary results with physiologically based models of CPK release from the infarct and its disappearance from the circulation suggest that release may be diffusion-limited and that the CPK disappearance rate is relatively uninfluenced by profound hemodynamic derangements or myocardial infarctions per se. The substantial inactivation of CPK in lymph in vitro and in situ underscores the importance of defining factors influencing the proportion of a biochemical marker depleted from necrotic myocardium appearing in blood, since the proportion is one parameter used in models employed to quantitatively estimate irreversible ischemic injury.